Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010217 | 1.00 | P2RX7 (0.85) | P2RX7 | |
| SCHEMBL2007598 | 1.00 | P2RX7 (0.85) | P2RX7 | |
| SCHEMBL2010222 | 1.00 | P2RX7 (0.85) | P2RX7 | |
| SCHEMBL2005583 | 0.96 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL3670038 | 0.96 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL2005585 | 0.96 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL17323934 | 0.92 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL17324016 | 0.92 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL17324059 | 0.92 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL17323944 | 0.92 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | claimed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | claimed |
| EP-2139879-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | claimed |
| US-7964616-B2 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | claimed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | claimed |
| CN-106573907-B | Quinoline derivatives and their use for neurodegenerative diseases | 默克专利有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | disclosed |
| EP-2139879-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2139879-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-7964616-B2 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964616-B2 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964616-B2 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008114002-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885 |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | CNKSR1, HRH4, HRH1 | P2RX7 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.